Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 189
Filter
Add more filters










Publication year range
1.
Br J Pharmacol ; 152(7): 1131-9, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17767169

ABSTRACT

BACKGROUND AND PURPOSE: The mechanism for the development of post-haemorrhagic cerebral vasospasm after subarachnoid haemorrhage (SAH) still remains unknown. EXPERIMENTAL APPROACH: We investigated the role of thrombin and its receptor PAR1 in the development of hyper-contractility of the basilar artery in a rabbit double haemorrhage model, which received two injections of autologous blood into the cisterna magna. KEY RESULTS: In the basilar artery isolated from the control rabbits, thrombin, only at 10 units ml(-1), induced a transient endothelium-dependent relaxation and a slight smooth muscle contraction. In SAH, the contractile response to thrombin was markedly enhanced, while the endothelium-dependent relaxant effect of thrombin remained unchanged. The enhancement of the contractile responses was also observed in the absence of endothelium and thrombin induced an enhanced contraction at concentrations higher than 0.3 units ml(-1). The contractile response to PAR1-activating peptide was also enhanced after SAH. However, the contractile responses to high K+ and endothelin-1, and the myofilament Ca2+-sensitivity remained unchanged after SAH. An immunoblot analysis suggested the up-regulation of PAR1 in the smooth muscle of the basilar artery. The heparinization of blood before injection prevented the enhancement of the contractile responses to thrombin and PAR1-activating peptide. CONCLUSIONS AND IMPLICATIONS: The present study demonstrated, for the first time, that the contractile response of the basilar artery to thrombin was markedly enhanced after SAH. Mechanistically, our findings suggested that the activation of thrombin following hemorrhage up-regulated the expression of PAR1, thereby inducing the hyper-responsiveness to thrombin.


Subject(s)
Basilar Artery/physiopathology , Receptor, PAR-1/metabolism , Subarachnoid Hemorrhage/physiopathology , Thrombin/metabolism , Vasospasm, Intracranial/physiopathology , Animals , Basilar Artery/drug effects , Basilar Artery/metabolism , Calcium/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Heparin/pharmacology , Male , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiopathology , Organ Culture Techniques , Potassium/pharmacology , Rabbits , Receptor, PAR-1/agonists , Receptor, PAR-1/biosynthesis , Thrombin/pharmacology , Up-Regulation/drug effects , Vasoconstriction/drug effects
2.
Br J Pharmacol ; 151(7): 1014-24, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17549043

ABSTRACT

BACKGROUND AND PURPOSE: The intravesical administration of dimethyl sulphoxide (DMSO) is used to alleviate the symptoms of interstitial cystitis. We investigated the relaxant effect of DMSO and its underlying mechanism in the detrusor muscle. EXPERIMENTAL APPROACH: The effects of DMSO on contraction, on Ca2+ sensitivity of myofilaments, and on myosin light chain (MLC) phosphorylation were investigated in both intact and alpha-toxin-permeabilized strips of rabbit detrusor muscle. KEY RESULTS: In fura-PE3-loaded strips, DMSO (>1%) induced a significant relaxation during sustained contractions induced by 60 mM K+-depolarization or 10 microM carbachol, while having no effect on the [Ca2+](i) level. DMSO decreased the level of MLC phosphorylation during the contractions induced by 60 mM K+ and 10 microM carbachol. DMSO also inhibited both the contraction and MLC phosphorylation induced by calyculin-A in intact strips. In the alpha-toxin-permeabilized preparations, DMSO relaxed the Ca2+-induced contraction and also inhibited the tension development induced by a stepwise increment of Ca2+ concentrations. Such a relaxant effect of DMSO was enhanced in the presence of phosphate. CONCLUSIONS AND IMPLICATIONS: DMSO relaxes rabbit detrusor muscle by decreasing the Ca2+ sensitivity of myofilaments. Inhibition of the kinase activities involved in myosin phosphorylation may play a major role in DMSO-induced Ca2+ desensitization. Inhibition of the cross-bridge cycling at the step of phosphate release may also contribute to the relaxant effect of DMSO. Such relaxant effects of DMSO could be linked to the therapeutic effect of DMSO in interstitial cystitis.


Subject(s)
Calcium/pharmacology , Dimethyl Sulfoxide/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Urinary Bladder/drug effects , Actins/metabolism , Analgesics, Non-Narcotic/pharmacology , Androstadienes/pharmacology , Animals , Aorta/drug effects , Aorta/metabolism , Aorta/physiology , Calcium/metabolism , Calmodulin/pharmacology , Carbachol/pharmacology , Cholinergic Agonists/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , In Vitro Techniques , Male , Muscle Relaxation/drug effects , Muscle, Smooth/physiology , Myosin Light Chains/metabolism , Myosin-Light-Chain Kinase/metabolism , Phosphates/metabolism , Phosphorylation/drug effects , Potassium Chloride/pharmacology , Rabbits , Rats , Type C Phospholipases/pharmacology , Urinary Bladder/metabolism , Urinary Bladder/physiology , Wortmannin
3.
Br J Pharmacol ; 150(4): 434-44, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17220909

ABSTRACT

BACKGROUND AND PURPOSE: Although vascular smooth muscle cells are known to express the Na+-Ca2+ exchanger (NCX), its functional role has remained unclear, mainly because of its relatively low expression. We thus investigated the involvement of NCX in the mechanism for the forskolin-induced vaso-relaxation, using wild type (WT) and transgenic (TG) mice that specifically over-express NCX1.3 in smooth muscle. EXPERIMENTAL APPROACH: We examined the relaxing effect of forskolin during the pre-contraction induced by 100 nM U46619, a thromboxane A2 analogue in the mouse isolated thoracic aorta. We also measured the intracellular Ca2+ concentration ([Ca2+]i) in fura-PE3-loaded aortic strips. KEY RESULTS: The forskolin-induced decreases in [Ca2+]i and tension were much greater in aortas from TG mice than in those from WT mice. In a low Na+ solution, forskolin-induced decreases in [Ca2+]i and tension were greatly inhibited in both groups of aortas. In WT aortas, the presence of 100 nM SEA0400, an NCX inhibitor, had only a little effect on the forskolin-induced decreases in [Ca2+]i, but inhibited the forskolin-induced relaxation. However, in TG aortas, the presence of SEA0400 greatly inhibited the forskolin-induced decreases in [Ca2+]i and tension. CONCLUSIONS AND IMPLICATIONS: The NCX was involved in the forskolin-induced reduction of [Ca2+]i and tension in the mouse thoracic aorta. Measurement of [Ca2+]i and tension in aortas of the TG mouse is thus considered to be a useful tool for evaluating the role of NCX in vascular tissue.


Subject(s)
Cyclic AMP/physiology , Muscle, Smooth, Vascular/physiology , Sodium-Calcium Exchanger/physiology , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Aniline Compounds/pharmacology , Animals , Aorta/cytology , Aorta/drug effects , Aorta, Thoracic/cytology , Aorta, Thoracic/drug effects , Calcium/metabolism , Colforsin/antagonists & inhibitors , Colforsin/pharmacology , Dinoprost/pharmacology , Dogs , Fluorescent Dyes , Fluorometry , Fura-2/analogs & derivatives , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle Relaxation/physiology , Phenyl Ethers/pharmacology , Sodium/physiology , Sodium-Calcium Exchanger/genetics , Vasoconstrictor Agents/pharmacology
4.
Kidney Int ; 69(2): 288-97, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16408118

ABSTRACT

We reported previously that various radiocontrast media cause apoptosis in porcine proximal tubular (LLC-PK(1)) cells, in which reduction in B-cell lymphoma (Bcl)-2 expression and caspase-3 activation are implicated. In the present study, we investigated a role for ceramide in radiocontrast media-induced apoptosis in renal tubular cells. LLC-PK(1) cells were exposed to radiocontrast media for 30 min, followed by incubation for 24 h in normal medium. Cell viability was assessed by 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt assay, while apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling stain. Immunofluorescent stains were performed using antibodies against phosphorylated Akt (pAkt) and cAMP response element binding protein (CREB) (pCREB), and ceramide. The mRNA expression and protein content of Bcl-2 were determined by reverse transcriptase-polymerase chain reaction and enzyme immunoassay, respectively. In vivo model of contrast-induced renal injury was induced in mice with unilateral renal occlusion. The cell injury induced by the nonionic radiocontrast medium ioversol was reversed by inhibiting de novo ceramide synthesis with fumonisin B(1) (FB(1)) and L-cycloserine, but not by suppressing sphingomyelin breakdown with D609. FB(1) reversed ioversol-induced decrease in the immunoreactivities of pAkt and pCREB, reduction in Bcl-2 expression and caspase-3 activation. Like ioversol, C2 ceramide and the Akt inhibitor Src homology-6 induced apoptosis by reducing pAkt and pCREB-like immunoreactivities, lowering Bcl-2 expression and enhancing caspase-3 activity. Indeed, various radiocontrast media, excluding iodixanol which showed the least nephrotoxicity, enhanced ceramide-like immunoreactivity. The role for de novo ceramide synthesis was also shown in the in vivo model of radiocontrast nephropathy. We demonstrated here for the first time that the enhancement of de novo ceramide synthesis contributes to radiocontrast nephropathy.


Subject(s)
Ceramides/biosynthesis , Contrast Media/toxicity , Kidney Tubules/drug effects , Triiodobenzoic Acids/toxicity , Acetylglucosamine/urine , Animals , Apoptosis , Cell Survival/drug effects , Cells, Cultured , Cyclic AMP Response Element-Binding Protein/metabolism , Fumonisins/pharmacology , Insulin-Like Growth Factor I/pharmacology , Kidney Tubules/pathology , Mice , Mitochondria/drug effects , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/analysis , Proto-Oncogene Proteins c-bcl-2/genetics , Reactive Oxygen Species , Swine
5.
Arterioscler Thromb Vasc Biol ; 21(12): 1896-901, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11742861

ABSTRACT

3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, so-called statins, reduce the relative risk of a major coronary event by lowering the serum cholesterol level. In addition, statins may confer beneficial effects by cholesterol-lowering independent mechanisms, which are incompletely characterized. Because angiotensin II (Ang II) plays crucial roles in the pathogenesis of cardiovascular diseases, we examined the effect of statins on the expression of the Ang II type 1 receptor (AT(1)-R) in cultured vascular smooth muscle cells (VSMCs). Cerivastatin and fluvastatin reduced the AT(1)-R mRNA and the AT(1)-R protein levels; however, pravastatin lacked this effect. Cerivastatin and fluvastatin suppressed the AT(1)-R promoter activity measured by luciferase assay but did not affect AT(1)-R mRNA stability, suggesting that the suppression occurs at the transcriptional level. Coincubation of VSMCs with mevalonate or geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate reversed the cerivastatin-induced AT(1)-R downregulation. Overexpression of dominant-negative Rho A also suppressed AT(1)-R mRNA expression. Treatment with cerivastatin for 24 hours reduced the calcium response of VSMCs to Ang II. Taken together, statins downregulate AT(1)-R expression through a mevalonate-dependent, geranylgeranyl pyrophosphate-dependent, and Rho A-dependent manner and attenuate the biological function of Ang II. Downregulation of AT(1)-R may contribute to the cholesterol-independent beneficial effect of statins on the cardiovascular system.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Muscle, Smooth, Vascular/metabolism , Receptors, Angiotensin/drug effects , Animals , Binding Sites/drug effects , Cells, Cultured , Down-Regulation , Fatty Acids, Monounsaturated/pharmacology , Fluvastatin , Gene Expression/drug effects , Indoles/pharmacology , Mevalonic Acid/pharmacology , Pyridines/pharmacology , RNA, Messenger/drug effects , Rats , Rats, Sprague-Dawley , Receptor, Angiotensin, Type 1 , Receptors, Angiotensin/genetics , Receptors, Angiotensin/metabolism
6.
Exp Cell Res ; 271(2): 356-67, 2001 Dec 10.
Article in English | MEDLINE | ID: mdl-11716548

ABSTRACT

By plating porcine aortic endothelial cells at two different densities and thereby inducing two different time courses of contact-induced growth arrest, the temporal correlation between p27(Kip1) expression and cell cycle progression was investigated. When the quiescent cells were replated, they synchronously entered S phase with a peak at 20 h in both cases, while the cells plated at 25 and 80% of confluent densities exited the cell cycle by 96 and 48 h, respectively. Nuclear p27(Kip1) disappeared when the cells reentered the cell cycle and then recovered when the cells exited the cell cycle. The change in p27(Kip1) was associated with a concomitant change in Kip1 mRNA. The p27(Kip1) degradation activity did not increase in the cells reentering the cell cycle, nor did it decrease in the cells exiting the cell cycle. The Kip1 mRNA stability decreased in the growing cells and increased in the cells exiting the cell cycle and at confluence. A nuclear run-on assay revealed a close correlation between the Kip1 transcriptional activity and the level of Kip1 mRNA. We conclude that the cell-cell contact up-regulated the Kip1 gene transcription and increased the Kip1 mRNA stability, which was related to the recovery of p27(Kip1) protein during contact-induced growth arrest in endothelial cells.


Subject(s)
Cell Communication/genetics , Cell Cycle Proteins/metabolism , Cell Cycle/genetics , Endothelium, Vascular/metabolism , Trans-Activators , Transcription, Genetic/physiology , Tumor Suppressor Proteins/metabolism , Up-Regulation/genetics , Animals , Biological Assay , Bromodeoxyuridine , Cell Adhesion/genetics , Cell Culture Techniques/methods , Cell Cycle Proteins/genetics , Cell Cycle Proteins/pharmacology , Cell Extracts/analysis , Cells, Cultured , Cyclin-Dependent Kinase Inhibitor p27 , Cyclins/metabolism , Cytoskeletal Proteins/metabolism , Dose-Response Relationship, Drug , Endothelium, Vascular/cytology , Enzyme Inhibitors/pharmacology , Fluorescent Antibody Technique , RNA, Messenger/metabolism , Swine , Time Factors , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/pharmacology , beta Catenin
7.
Br J Pharmacol ; 134(4): 815-26, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11606322

ABSTRACT

1. To investigate the mechanism underlying the trypsin-induced endothelium-dependent relaxation, cytosolic Ca(2+) concentration ([Ca(2+)](i)) and tension development of smooth muscle were simultaneously monitored in the porcine coronary artery, and [Ca(2+)](i) of in situ endothelial cells were monitored in the porcine aortic valvular strips, using fura-2 fluorometry. 2. During the contraction induced by 30 nM U46619, a thromboxane A(2) analogue, 100 nM trypsin induced a rapid transient significant decrease in both [Ca(2+)](i) (from 67.9+/-5.1 to 15.7+/-4.4%) and tension (from 97.5+/-9.2 to 16.8+/-3.5%) of smooth muscle only in the presence of endothelium (100% level was assigned to the level obtained with the 118 mM K(+)-induced contraction). [Ca(2+)](i) and the tension thus returned to the levels prior to the application of trypsin by 5 and 10 min, respectively. 3. The initial phase of this relaxation was partly inhibited by 100 microM N(omega)-nitro-L-arginine (L-NOARG), and was completely inhibited by L-NOARG plus 40 mM K(+) or L-NOARG plus 100 nM charybdotoxin and 100 nM apamin, while the late phase of the relaxation was inhibited by L-NOARG alone. 4. Trypsin induced a transient [Ca(2+)](i) elevation in the endothelial cells mainly due to the Ca(2+) release from the intracellular stores, at the concentrations (1 - 100 nM) similar to those required to induce relaxation. 5. In conclusion, trypsin induced an elevation in [Ca(2+)](i) mainly due to Ca(2+) release in endothelial cells, and thereby caused endothelium-dependent relaxation. The early phase of relaxation was due to nitric oxide and hyperpolarizing factors, while the late phase was mainly due to nitric oxide in the porcine coronary artery.


Subject(s)
Coronary Vessels/drug effects , Endothelium, Vascular/physiology , Trypsin/pharmacology , Vasodilation/drug effects , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Adenosine Triphosphate/pharmacology , Animals , Aortic Valve/drug effects , Aortic Valve/metabolism , Apamin/pharmacology , Biological Factors/physiology , Calcium/metabolism , Calcium/pharmacology , Charybdotoxin/pharmacology , Coronary Vessels/physiology , Dose-Response Relationship, Drug , Endothelium, Vascular/cytology , Enzyme Inhibitors/pharmacology , In Vitro Techniques , Indomethacin/pharmacology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiology , Nickel/pharmacology , Nitric Oxide/physiology , Nitric Oxide Synthase/antagonists & inhibitors , Nitroarginine/pharmacology , Oligopeptides/pharmacology , Potassium Channel Blockers , Receptor, PAR-2 , Receptors, Thrombin/antagonists & inhibitors , Substance P/pharmacology , Swine , Time Factors , Vasoconstrictor Agents/pharmacology
8.
Br J Pharmacol ; 134(1): 168-78, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11522609

ABSTRACT

1. To elucidate the mechanism of the relaxation mediated by endothelium-derived hyperpolarizing factors (EDHFs), the effect of brefeldin A, a membrane transport blocker, on cytosolic Ca(2+) concentration ([Ca(2+)]i) and tension was determined in the porcine coronary arterial strips. We also examined the effect of brefeldin A on [Ca(2+)]i in the endothelial cells of the porcine aortic valve. 2. In the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NOARG), both bradykinin and substance P induced a transient decrease in [Ca(2+)]i and tension in arterial strips contracted with 100 nM U46619 (thromboxane A2 analogue). A 6 h pre-treatment with 20 microg ml(-1) brefeldin A abolished the bradykinin-induced relaxation, while it had no effect on the substance P-induced relaxation. 3. In the absence of indomethacin and L-NOARG, brefeldin A had no effect on the bradykinin-induced relaxation during the contraction induced by U46619 or 118 mM K(+). 4. The indomethacin/L-NOARG-resistant relaxation induced by bradykinin was completely inhibited by 3 mM tetrabutylammonium (non-specific Ca(2+)-activated K(+) channel blocker), while that induced by substance P was not inhibited by 3 mM tetrabutylammonium or 1 mM 4-aminopyridine (voltage-dependent K(+) channels blocker) alone, but completely inhibited by their combination. 5. Brefeldin A had no effect on the [Ca(2+)]i elevation in endothelial cells induced by bradykinin or substance P. 6. In conclusion, bradykinin produce EDHF in a brefeldin A-sensitive mechanism in the porcine coronary artery. However, this mechanism is not active in a substance P-induced production of EDHF, which thus suggests EDHF to be more than a single entity.


Subject(s)
Bradykinin/pharmacology , Brefeldin A/pharmacology , Coronary Vessels/drug effects , Vasodilation/drug effects , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , 4-Aminopyridine/pharmacology , Animals , Apamin/pharmacology , Biological Factors/physiology , Calcium/metabolism , Coronary Vessels/physiology , Dose-Response Relationship, Drug , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Female , In Vitro Techniques , Indomethacin/pharmacology , Male , Nitroarginine/pharmacology , Peptides/pharmacology , Potassium/pharmacology , Potassium Channel Blockers , Quaternary Ammonium Compounds/pharmacology , Substance P/pharmacology , Swine , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology
9.
Br J Pharmacol ; 133(8): 1276-85, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11498513

ABSTRACT

1. The mechanism of trypsin-induced contraction in the rat myometrium was investigated using front-surface fluorimetry on fura-PE3-loaded strips. The expression of protease-activated receptors (PARs) in the rat myometrium was determined by reverse transcription polymerase chain reaction (RT - PCR). 2. In non-pregnant rats, 10 microM trypsin developed a force of up to 30.5 +/- 5.1% of that obtained during the 40 mM K(+)-depolarization-induced contraction. In pregnant rats, the maximal level of the cytosolic Ca(2+) concentration and tension obtained with 3 microM trypsin was 143.2 +/- 6.0% and 63.2 +/- 7.9%, respectively. The depletion of the extracellular Ca2+ abolished the trypsin-induced contraction. 3. Trypsin-induced contraction was abolished by the pre-treatment of a serine protease inhibitor. PAR1-activating peptide (PAR1-AP) caused a potent contraction of the myometrium, while neither PAR2-AP nor PAR4-AP induced any contraction. 4. RT - PCR analysis detected the expression of PAR1 mRNA. However, neither PAR2 nor PAR4 mRNA was detected in the rat myometrium. 5. Once the strips were stimulated with thrombin, the subsequent application of thrombin failed to induce any contraction, while trypsin induced a contraction similar to that observed without the pre-stimulation with thrombin. Once the strip was stimulated with trypsin, neither trypsin nor thrombin induced any contraction. The response to PAR1-AP remained after the pre-stimulation with thrombin and trypsin. 6. In conclusion, PAR1 was the only known receptor for trypsin expressed in the rat myometrium, but it was suggested to be cleaved and inactivated by trypsin. Trypsin was thus suggested to contract the rat myometrium via a novel type of PAR, which might be upregulated during pregnancy.


Subject(s)
Calcium Signaling/drug effects , Myometrium/drug effects , Receptors, Thrombin/metabolism , Trypsin/pharmacology , Uterine Contraction/drug effects , Animals , Calcium/metabolism , Female , Fluorometry , Myometrium/metabolism , Phenylmethylsulfonyl Fluoride/analogs & derivatives , Phenylmethylsulfonyl Fluoride/pharmacology , Pregnancy , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Receptor, PAR-1 , Receptor, PAR-2 , Receptors, Thrombin/genetics , Thrombin/pharmacology
10.
J Physiol ; 534(Pt 3): 701-11, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11483701

ABSTRACT

1. To determine the mechanism of bradykinin-induced production of endothelium-derived contracting factors, we monitored the changes in cytosolic Ca(2+) concentration ([Ca(2+)](i)) in in situ endothelial cells in porcine aortic valvular strips and the changes in [Ca(2+)](i) of smooth muscle cells and force in porcine interlobar renal arterial strips using front-surface fluorometry of fura-2. 2. In the presence of N(omega)-nitro-L-arginine methyl ester, bradykinin caused an endothelium-dependent transient elevation of [Ca(2+)](i) and contraction in smooth muscle in the interlobar renal artery. This contraction was completely inhibited by a prostaglandin H(2)/thromboxane A(2) receptor antagonist. 3. In the absence of extracellular Ca(2+), bradykinin failed to induce contraction. However, replenishing extracellular Ca(2+) to 0.75 mM and higher induced an instantaneous contraction. However, replenishing Ca(2+) per se did not induce any contraction in the absence of bradykinin. Pretreatment with either 10(-5) M 1-(beta-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenethyl)-1H-imidazole hydrochloride (SKF96365) or 0.2 mM Ni(2+) abolished the contraction induced by bradykinin in the presence of extracellular Ca(2+). 4. Treatment with 10(-5) M indomethacin completely inhibited the contractile response induced by Ca(2+) replenishment, regardless of the timing of its application, before or after the application of bradykinin. 5. In endothelial cells in the valvular strips, bradykinin caused a transient [Ca(2+)](i) elevation in the presence of 1.25 mM extracellular Ca(2+), but [Ca(2+)](i) returned to the resting level within 10 min. Neither 10(-5) M SKF96365 nor 0.2 mM Ni(2+) had any effect on the peak [Ca(2+)](i) elevation, but decreased [Ca(2+)](i) in the declining phase. In the absence of extracellular Ca(2+), bradykinin induced a transient [Ca(2+)](i) elevation to a level similar to that seen in the presence of 1.25 mM extracellular Ca(2+). However, [Ca(2+)](i) then rapidly returned to the prestimulation level within 5 min. Subsequent Ca(2+) replenishment to 0.75 mM and higher in the presence of bradykinin elevated [Ca(2+)](i) to significantly higher levels than the resting level seen in the media containing 1.25 mM Ca(2+). 6. In conclusion, Ca(2+) influx in the endothelial cells is essential for bradykinin to induce endothelium-dependent contraction in the porcine interlobar renal artery.


Subject(s)
Bradykinin/pharmacology , Calcium/metabolism , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiology , Renal Artery/physiology , Vasoconstriction/physiology , Animals , Calcium Channel Blockers/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Extracellular Space/metabolism , Imidazoles/pharmacology , In Vitro Techniques , Indomethacin/pharmacology , Nickel/pharmacology , Renal Artery/drug effects , Swine
11.
J Cereb Blood Flow Metab ; 21(7): 876-85, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11435800

ABSTRACT

Fasudil hydrochloride (AT877, hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine hydrochloride, identical to HA1077) inhibits cerebral vasospasm after subarachnoid hemorrhage in experimental animals and humans. In the current study, the vasorelaxing mechanism of hydroxyfasudil, a hydroxylated metabolite of fasudil hydrochloride, was determined in the rabbit basilar artery. The effects of hydroxyfasudil on tension, intracellular Ca2+ concentration ([Ca2+]i), and phosphorylation of the myosin light chain were examined using the isolated and intact or permeabilized rabbit basilar artery without endothelium in vitro. In the intact rabbit basilar artery, hydroxyfasudil elicited a concentration-dependent relaxation of the artery precontracted with 1 nmol/L endothelin-1 (ET-1) plus 20 mmol/L KCl without any significant decrease in [Ca2+]i as determined by fura-2 microfluorometry (IC50: 5.1 +/- 4.6 micromol/L). The relaxation induced by hydroxyfasudil was accompanied with dephosphorylation of the myosin light chain. In the permeabilized preparation, hydroxyfasudil inhibited the contraction induced by ET-1, guanosine 5'-O-(3-thiotriphosphate), or the catalytic subunit of rho-associated kinase, but it did not inhibit Ca2+-induced contraction under the condition of inhibited myosin light chain phosphatase. Hydroxyfasudil showed a greater relaxant effect under decreased adenosine triphosphate (ATP) levels. The present study indicated that hydroxyfasudil relaxes the rabbit basilar artery mainly by disinhibiting myosin light chain phosphatase through the inhibition of rho-associated kinase and that this effect depends on the intracellular ATP concentration.


Subject(s)
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/metabolism , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Muscle Relaxation/drug effects , Muscle, Smooth, Vascular/drug effects , Phosphoprotein Phosphatases/metabolism , Vasodilator Agents/pharmacology , Adenosine Triphosphate/administration & dosage , Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/pharmacology , Animals , Basilar Artery/drug effects , Basilar Artery/physiology , Calcium/metabolism , Calcium/pharmacology , Endothelin-1/pharmacology , Enzyme Activation/drug effects , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Kinetics , Male , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/physiology , Myosin-Light-Chain Phosphatase , Phorbol 12,13-Dibutyrate/pharmacology , Protein Kinase C/metabolism , Rabbits
12.
Br J Pharmacol ; 133(4): 529-38, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11399670

ABSTRACT

The mechanism underlying the LTC(4)-induced contraction of guinea-pig taenia coli was determined using the simultaneous measurements of [Ca(2+)](i) and force in whole muscle preparations. Additional experiments were performed in receptor coupled permeabilized preparation. For comparison purposes, the contraction which was induced by a typical G-protein mediated agonist, carbachol was also characterized. LTC(4) induced a contraction in the guinea-pig taenia coli in a concentration-dependent manner. The maximal response was obtained at 100 nM and the EC(50) value was 5.4+/-1.9 nM. Both LTC(4) and carbachol induced increases in [Ca(2+)](i) and force. The maximum force induced by 100 nM LTC(4) was significantly smaller than that induced by 10 microM carbachol, although an increase in [Ca(2+)](i) produced by both agonists was similar. In the permeabilized preparations, carbachol, but not LTC(4), induced an additional force development at a fixed Ca(2+) concentration. LTC(4) induced no increase in [Ca(2+)](i) and force in the Ca(2+)-free solution, while carbachol induced transient increases in both [Ca(2+)](i) and force in a Ca(2+)-free solution. Both diltiazem and SK&F 96365 significantly inhibited the LTC(4)- and carbachol-induced increases in [Ca(2+)](i) and force in normal PSS. The inhibitory pattern of [Ca(2+)](i) by these drugs was also similar. We thus conclude that LTC(4) induces the contraction of the guinea-pig taenia coli mainly through Ca(2+) influx via both the diltiazem-sensitive and SK&F 96365-sensitive Ca(2+) channels, without affecting either the Ca(2+)-sensitivity or the intracellular Ca(2+) release. These results indicated that the mechanism underlying the LTC(4)-induced contraction differs greatly from that for conventional G-protein mediated agonists, such as carbachol.


Subject(s)
Calcium/metabolism , Colon/drug effects , Leukotriene C4/pharmacology , Muscle Contraction/drug effects , Animals , Calcium Channel Blockers/pharmacology , Carbachol/pharmacology , Cardiotonic Agents/pharmacology , Chelating Agents/pharmacology , Colon/physiology , Diltiazem/pharmacology , Drug Interactions , Egtazic Acid/pharmacology , Guinea Pigs , Imidazoles/pharmacology , In Vitro Techniques , Permeability , Type C Phospholipases/pharmacology
13.
Br J Pharmacol ; 132(1): 111-8, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11156567

ABSTRACT

1. An unsaturated fatty acid, leukotriene C(4) (LTC(4)), has a potent contractile effect on human airway smooth muscle, and has been implicated in the pathogenesis of human asthma. Using front-surface fluorometry with fura-PE3, the effect of LTC(4) on the intracellular Ca(2+) concentration ([Ca(2+)](i)) and tension were investigated in porcine tracheal smooth muscle strips. 2. The application of LTC(4) induced little or no contraction despite a small and transient increase in [Ca(2+)](i). In the presence of LTC(4), however, the contractions evoked by high K(+) depolarization or a low concentration of carbachol (CCh) were markedly enhanced without inducing any changes in the [Ca(2+)](i) levels, thus indicating that LTC(4) increases the Ca(2+) responsiveness of the contractile apparatus. This LTC(4)-induced increase in Ca(2+) responsiveness could partly be reproduced in the permeabilized preparation of tracheal smooth muscle strips. 3. The LTC(4)-induced enhancement of contraction was accompanied by an increase in myosin light chain (MLC) phosphorylation and was blocked by a rho kinase inhibitor (Y-27632), but not by either a PKC inhibitor (calphostin C) or a tyrosine kinase inhibitor (genistein). 4. These results indicated that, in porcine tracheal smooth muscle, LTC(4) enhances the contraction by increasing the Ca(2+) responsiveness of the contractile apparatus in a MLC phosphorylation dependent manner, possibly through the activation of the rho-rho kinase pathway.


Subject(s)
Amides/pharmacology , Enzyme Inhibitors/pharmacology , Fura-2/analogs & derivatives , Leukotriene C4/pharmacology , Muscle, Smooth/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pyridines/pharmacology , Animals , Calcium/metabolism , Carbachol/pharmacology , Fluorescent Dyes , In Vitro Techniques , Intracellular Signaling Peptides and Proteins , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle, Smooth/physiology , Myosin Light Chains/metabolism , Phosphorylation , Swine , Trachea/drug effects , Trachea/physiology , Type C Phospholipases/pharmacology , rho-Associated Kinases
14.
J Biol Chem ; 276(9): 6073-82, 2001 Mar 02.
Article in English | MEDLINE | ID: mdl-11067852

ABSTRACT

Myosin light chain phosphatase consists of three subunits, a 38-kDa catalytic subunit, a large 110-130-kDa myosin binding subunit, and a small subunit of 20-21 kDa. The catalytic subunit and the large subunit have been well characterized. The small subunit has been cloned and studied from smooth muscle, but little is known about its function and specificity in the other muscles such as cardiac muscle. In this study, cDNAs for heart-specific small subunit isoforms, hHS-M(21), were isolated and characterized. Evidence was obtained from an analysis of genome to suggest that the small subunit was the product of the same gene as the large subunit. Using permeabilized renal artery preparation and permeabilized cardiac myocytes, it was shown that the small subunit increased sensitivity to Ca(2+) in muscle contraction. It was also shown using an overlay assay that hHS-M(21) bound the large subunit. Mapping experiments demonstrated that the binding domain and the domain involved in the increasing Ca(2+) sensitivity mapped to the same N-terminal region of hHS-M(21). These observations suggest that the heart-specific small subunit hHS-M(21) plays a regulatory role in cardiac muscle contraction by its binding to the large subunit.


Subject(s)
Myocardium/enzymology , Phosphoprotein Phosphatases/genetics , Amino Acid Sequence , Animals , Base Sequence , Calcium/metabolism , Calcium/pharmacology , DNA, Complementary/isolation & purification , Humans , Molecular Sequence Data , Myocardial Contraction/drug effects , Myosin-Light-Chain Phosphatase , Phosphoprotein Phosphatases/chemistry , Phosphoprotein Phosphatases/physiology , Phosphorylation , Protein Subunits , Rats , Swine , Vasoconstriction/drug effects
15.
Biochem J ; 353(Pt 1): 51-57, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11115398

ABSTRACT

p27(Kip1) is an inhibitor of cyclin-dependent kinases. It has been implicated as having a role in the induction of growth arrest at the G(1) phase of the cell cycle in response to anti-mitogenic signals such as cell contact and serum starvation. Proteasome-mediated degradation plays an important role in the rapid inactivation of p27(Kip1), causing quiescent cells to re-enter the cell cycle. Although the existence of a second isoform has been suggested, no such isoform was isolated. Through screening of a cDNA library derived from growth-arrested confluent porcine endothelial cells, we obtained clones for a novel isoform of p27(Kip1) in addition to the original isoform. The novel isoform differed from the original isoform at the C-terminus. The tissue-specific expression of the original and novel isoforms was demonstrated at the mRNA and protein levels. An in vitro degradation assay demonstrated this novel isoform to be resistant to proteasome-mediated destruction. The expression as a fusion protein with green fluorescent protein revealed this isoform to be targeted to the nucleus by a bipartite nuclear-localization signal with a C-terminal part different from that of the original isoform. The expression of the novel isoform caused the growth arrest of HeLa cells and an accumulation of cells in the G(0)/G(1) phase, and this effect was similar to that seen with the original isoform. The present study suggests that the novel isoform functions as a negative regulator of the cell cycle, and may play a distinct role. The novel isoform was named p27(Kip1R) because of its resistance to degradation.


Subject(s)
Cell Cycle Proteins , Microtubule-Associated Proteins/genetics , Microtubule-Associated Proteins/metabolism , Swine/genetics , Tumor Suppressor Proteins , Alternative Splicing/genetics , Amino Acid Sequence , Animals , Apoptosis , Cell Cycle , Cell Nucleus/chemistry , Cloning, Molecular , Cyclin-Dependent Kinase Inhibitor p27 , Cysteine Endopeptidases/metabolism , Endothelium/cytology , Endothelium/metabolism , Flow Cytometry , Gene Expression Profiling , HeLa Cells , Humans , Microtubule-Associated Proteins/chemistry , Molecular Sequence Data , Multienzyme Complexes/metabolism , Nuclear Localization Signals , Organ Specificity , Proteasome Endopeptidase Complex , Protein Isoforms/chemistry , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/analysis , RNA, Messenger/genetics , Recombinant Fusion Proteins/metabolism , Sequence Alignment
16.
Clin Calcium ; 11(4): 411-7, 2001 Apr.
Article in Japanese | MEDLINE | ID: mdl-15775534

ABSTRACT

The contractile tone of the vascular smooth muscle plays an important role on the regulation of the blood pressure as well as the local perfusion of the important organs such as the heart and brain. The importance of the Ca(2+) sensitivity in the regulation of the vascular tone has been established by the development of the simultaneous measurements of intracellular Ca(2+) concentration ( [Ca(2+)](i) ) and tension as well as that of the receptor coupled permeabilized preparation in the late 1980s. Recently, the mechanisms underlying the regulation of Ca(2+) sensitivity have been revealed. The increase in the Ca(2+) sensitivity involves the myosin phosphatase (MLCP) inhibition mediated by rhoA-rho kinase system and PKC-CPI system. The decrease in the Ca(2+) sensitivity involves the PKA-mediated inhibition of myosin light chain kinase, the PKG-mediated activation of MLCP, and PKA- or PKG-mediated inactivation of rhoA. In this article, the regulation of the Ca(2+) sensitivity of the contractile apparatus of the vascular smooth muscle will be briefly reviewed.

17.
Anticancer Res ; 20(5B): 3363-73, 2000.
Article in English | MEDLINE | ID: mdl-11131636

ABSTRACT

Modulation of interferon-gamma effect by other drug may enhance its tumor specific activity. The apoptosis inducing effect of interferon-gamma and its modulation by cyclosporin-A or tacrolimus (FK-506) were investigated in in vitro and ex vivo experiments. We found that a combination of cyclosporin-A (CsA) and recombinant interferon-gamma (rIFN-gamma) induced significant apoptosis in all four types of human gastric carcinoma cells tested but not in normal cells such as human peripheral blood mononuclear cells (PBMCs), human omentum-derived mesothelial cells, or human umbilical vein endothelial cells (HUVECs) in vitro. Apoptosis was also induced by a combination of rIFN-gamma with FK-506 but not with rapamycin. Next, the apoptosis-inducing effect of endogenous IFN-gamma combined with cyclosporin-A was examined using clinical samples. A streptococcal preparation, OK-432, was administered intraperitoneally for the management of 12 gastric cancer patients with malignant ascites. None of the gascitic fluids obtained before the OK-432 injection showed detectable IFN-gamma level. The OK-432 injection induced a detectable IFN-gamma production ranging from 6 to 89 pg/mL in ascitic fluids from 9 out of the 12 patients. A combination of CsA with ascitic fluids collected after but not before OK-432 injection induced significant apoptosis in MK-1 cells, a gastric carcinoma cell line. A positive correlation was found between the IFN-gamma level and CsA-induced apoptosis. The CsA-induced apoptosis was also blocked by a specific antibody against human IFN-gamma. These results indicated that both recombinant and endogenous IFN-gamma can induce potent tumor-apoptosis when combined with CsA.


Subject(s)
Adenocarcinoma/pathology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/drug effects , Stomach Neoplasms/pathology , Adenocarcinoma/drug therapy , Adenocarcinoma/metabolism , Antineoplastic Agents/therapeutic use , Ascitic Fluid/metabolism , Cyclosporine/administration & dosage , Drug Interactions , Enzyme-Linked Immunosorbent Assay , Humans , Immunosuppressive Agents/administration & dosage , Injections, Intraperitoneal , Interferon-gamma/administration & dosage , Interferon-gamma/metabolism , Picibanil/therapeutic use , Recombinant Proteins , Stomach Neoplasms/drug therapy , Stomach Neoplasms/metabolism , Tacrolimus/administration & dosage , Tumor Cells, Cultured/drug effects
18.
Biochim Biophys Acta ; 1499(1-2): 109-121, 2000 Dec 11.
Article in English | MEDLINE | ID: mdl-11118643

ABSTRACT

The effects of progesterone and 17beta-estradiol on Ca(2+) signaling in in situ endothelial cells were investigated using front-surface fluorometry of fura-2-loaded strips of porcine aortic valve. Progesterone inhibited the thapsigargin-induced sustained [Ca(2+)](i) elevation (IC(50)=33.9 microM, n=4), while 17beta-estradiol added a transient [Ca(2+)](i) elevation. Progesterone and 17beta-estradiol had no significant effect on the thapsigargin-induced [Ca(2+)](i) elevations in the absence of extracellular Ca(2+). A Mn(2+)-induced decline of fluorescent intensity at 360 nm excitation was accelerated by thapsigargin. This acceleration was completely reversed by progesterone, but not by 17beta-estradiol. Progesterone inhibited, and 17beta-estradiol enhanced the endothelin-1 (ET-1)-induced [Ca(2+)](i) elevation, while both had no effect on the ET-1-induced Ca(2+) release observed in the absence of extracellular Ca(2+) or in the pertussis toxin-treated strips. Progesterone and 17beta-estradiol thus had different effects on Ca(2+) signaling, especially on Ca(2+) influx, in endothelial cells.


Subject(s)
Calcium/metabolism , Endothelium, Vascular/drug effects , Estradiol/pharmacology , Progesterone/pharmacology , Animals , Aortic Valve , Calcium/pharmacology , Calcium Signaling/drug effects , Dose-Response Relationship, Drug , Egtazic Acid , Endothelin-1/pharmacology , Endothelium, Vascular/metabolism , Fluorometry , Fura-2 , In Vitro Techniques , Manganese/metabolism , Swine , Thapsigargin/pharmacology
19.
J Clin Invest ; 106(12): 1521-30, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11120759

ABSTRACT

The endothelium plays an important role in maintaining vascular homeostasis by synthesizing and releasing several endothelium-derived relaxing factors, such as prostacyclin, nitric oxide (NO), and the previously unidentified endothelium-derived hyperpolarizing factor (EDHF). In this study, we examined our hypothesis that hydrogen peroxide (H(2)O(2)) derived from endothelial NO synthase (eNOS) is an EDHF. EDHF-mediated relaxation and hyperpolarization in response to acetylcholine (ACh) were markedly attenuated in small mesenteric arteries from eNOS knockout (eNOS-KO) mice. In the eNOS-KO mice, vasodilating and hyperpolarizing responses of vascular smooth muscle per se were fairly well preserved, as was the increase in intracellular calcium in endothelial cells in response to ACh. Antihypertensive treatment with hydralazine failed to improve the EDHF-mediated relaxation. Catalase, which dismutates H(2)O(2) to form water and oxygen, inhibited EDHF-mediated relaxation and hyperpolarization, but it did not affect endothelium-independent relaxation following treatment with the K(+) channel opener levcromakalim. Exogenous H(2)O(2) elicited similar relaxation and hyperpolarization in endothelium-stripped arteries. Finally, laser confocal microscopic examination with peroxide-sensitive fluorescence dye demonstrated that the endothelium produced H(2)O(2) upon stimulation by ACh and that the H(2)O(2) production was markedly reduced in eNOS-KO mice. These results indicate that H(2)O(2) is an EDHF in mouse small mesenteric arteries and that eNOS is a major source of the reactive oxygen species.


Subject(s)
Biological Factors/metabolism , Endothelium, Vascular/metabolism , Hydrogen Peroxide/metabolism , Acetylcholine/pharmacology , Animals , Antihypertensive Agents/pharmacology , Biological Factors/antagonists & inhibitors , Calcium/metabolism , Catalase/pharmacology , Endothelium, Vascular/drug effects , Gene Deletion , Hydralazine/pharmacology , Hydrogen Peroxide/antagonists & inhibitors , Membrane Potentials/drug effects , Mesenteric Arteries/drug effects , Mesenteric Arteries/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Fluorescence , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , Nitric Oxide Synthase Type III , Potassium Channel Blockers , Potassium Channels/metabolism , Reactive Oxygen Species/metabolism , Vasodilation/drug effects
20.
Circulation ; 102(15): 1834-9, 2000 Oct 10.
Article in English | MEDLINE | ID: mdl-11023940

ABSTRACT

BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPARgamma) activators, such as troglitazone (Tro), not only improve insulin resistance but also suppress the neointimal formation after balloon injury. However, the precise mechanisms have not been determined. Angiotensin II (Ang II) plays crucial roles in the pathogenesis of atherosclerosis, hypertension, and neointimal formation after angioplasty. We examined the effect of PPARgamma activators on the expression of Ang II type 1 receptor (AT(1)-R) in cultured vascular smooth muscle cells (VSMCs). METHODS AND RESULTS: AT(1)-R mRNA and AT(1)-R protein levels were determined by Northern blot analysis and radioligand binding assay, respectively. Natural PPARgamma ligand 15-deoxy-Delta(12,14)-prostaglandin J(2), as well as Tro, reduced the AT(1)-R mRNA expression and the AT(1)-R protein level. The PPARgamma activators also reduced the calcium response of VSMCs to Ang II. PPARgamma activators suppressed the AT(1)-R promoter activity measured by luciferase assay but did not affect the AT(1)-R mRNA stability, suggesting that the suppression occurs at the transcriptional level. CONCLUSIONS: PPARgamma activators reduced the AT(1)-R expression and calcium response to Ang II in VSMCs. Downregulation of AT(1)-R may contribute to the inhibition of neointimal formation by PPARgamma activators.


Subject(s)
Gene Expression Regulation , Muscle, Smooth, Vascular/metabolism , Prostaglandin D2/analogs & derivatives , Receptors, Angiotensin/genetics , Receptors, Cytoplasmic and Nuclear/physiology , Thiazolidinediones , Transcription Factors/physiology , Angiotensin II/metabolism , Animals , Calcium/metabolism , Cells, Cultured , Chromans/pharmacology , Down-Regulation , Muscle, Smooth, Vascular/physiology , Promoter Regions, Genetic , Prostaglandin D2/pharmacology , RNA Stability/physiology , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/metabolism , Receptors, Cytoplasmic and Nuclear/drug effects , Thiazoles/pharmacology , Transcription Factors/drug effects , Troglitazone
SELECTION OF CITATIONS
SEARCH DETAIL